When is it time for reverse transcription to start and go?
about
The macrophage: a therapeutic target in HIV-1 infectionHIV-1 nucleocapsid and ESCRT-component Tsg101 interplay prevents HIV from turning into a DNA-containing virus.The macrophage in HIV-1 infection: from activation to deactivation?7SL RNA is retained in HIV-1 minimal virus-like particles as an S-domain fragment.MoMuLV and HIV-1 nucleocapsid proteins have a common role in genomic RNA packaging but different in late reverse transcription.Function of a retrotransposon nucleocapsid proteinIdentification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex.Blocking premature reverse transcription fails to rescue the HIV-1 nucleocapsid-mutant replication defect.Structural determinants of TAR RNA-DNA annealing in the absence and presence of HIV-1 nucleocapsid protein.Role of HIV-1 RNA and protein determinants for the selective packaging of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus particlesNucleocapsid protein annealing of a primer-template enhances (+)-strand DNA synthesis and fidelity by HIV-1 reverse transcriptase.Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration.New insights into inhibition of human immunodeficiency virus type 1 replication through mutant tRNALys3.HIV-1-associated PKA acts as a cofactor for genome reverse transcription.Properties and functions of the nucleocapsid protein in virus assembly.Cell biology of retroviral RNA packaging.Implications of the nucleocapsid and the microenvironment in retroviral reverse transcription.Specific implications of the HIV-1 nucleocapsid zinc fingers in the annealing of the primer binding site complementary sequences during the obligatory plus strand transfer.Some mechanisms of FLIP expression in inhibition of HIV-1 replication in Jurkat cells, CD4+ T cells and PBMCs.Prototype foamy virus protease activity is essential for intraparticle reverse transcription initiation but not absolutely required for uncoating upon host cell entry.Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells.Secondary structure of the HIV reverse transcription initiation complex by NMR.Role of the primer activation signal in tRNA annealing onto the HIV-1 genome studied by single-molecule FRET microscopy.Structural insight into HIV-1 reverse transcription initiation in MAL-like templates (CRF01_AE, subtype G and CRF02_AG).Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence.A new role of the HIV-1 nucleocapsid in the spatiotemporal control of the reverse transcription throughout the virus replication cycle.Forced Complementation between Subgenomic RNAs: Does Human Immunodeficiency Type 1 Virus Reverse Transcription Occur in Viral Core, Cytoplasm, or Early Endosome?Design, synthesis and biological evaluation of TAR and cTAR binders as HIV-1 nucleocapsid inhibitors
P2860
Q26823236-BCF83F7D-C505-4FE8-8344-7A41149C8BA0Q30369511-F35C60F5-F64E-4542-A33B-434C2202695FQ33810779-81A5F3B5-AABC-466F-9126-C8654AE370ACQ34120220-5DA21C18-33AD-4260-A8CF-A3014F8A2625Q34511074-46903B29-D038-421D-ACC5-DD37A6046638Q34775636-5B319ED8-7946-4A8F-B714-D585C538CAAEQ35120765-08D9E2E9-3B53-41F1-9A88-12FEC66547C6Q35122165-D525DF44-6723-425A-9FF3-123259B03093Q35259243-9A7C2DC5-BBAA-459F-B023-6E0BAE58B688Q35468374-0F134BD7-4E60-44C4-AD21-E24439EA27DFQ35705540-43DF3E68-0215-4C06-8C67-65797A5510F6Q36598240-3F4FB527-ED99-4719-BB9B-C9EB6F68F340Q37320502-06E63F0B-0EFC-4346-8555-F146A7EB7DBAQ37430491-12EBC330-4961-41E4-BE7C-008794C8BBE2Q37820816-57EC2495-AB15-4868-B411-09682E25915BQ37892324-C4919787-7516-416D-ABAB-A0AAA658FE79Q37945202-A1E6DCCA-DEDA-4D10-AB50-2F4573042C59Q38335419-DBE63169-83E6-4FEA-8981-ACB6C10275D3Q39148849-D0CFACE8-F685-4670-A839-3E4C0188F60AQ39217498-5C5F3DA4-67FC-441E-AECE-8BF293B41AE4Q39843165-4E4012F8-911B-4BF2-9A9E-0A008B5581AFQ41265657-BC58D2C2-EF52-41D8-8993-A2700069902CQ41814101-535AB7FB-D4C6-4DED-A81F-C25E7FE81FD5Q42146725-5767EB64-D592-4186-867C-D1B65B2B6C91Q42235872-AB5D15F4-7137-4FC0-9538-A17C41C11037Q42860147-E4113326-3B91-4D84-A83B-6DEF29575145Q55645834-BA507567-3528-4683-BE20-3B188BA510AEQ56988804-5DB16525-6D7E-46EE-B5EC-BE6F528F67E6Q57588992-24C0CC8B-FCF7-4001-A02C-F4DADF0DD371
P2860
When is it time for reverse transcription to start and go?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
When is it time for reverse transcription to start and go?
@en
When is it time for reverse transcription to start and go?
@nl
type
label
When is it time for reverse transcription to start and go?
@en
When is it time for reverse transcription to start and go?
@nl
prefLabel
When is it time for reverse transcription to start and go?
@en
When is it time for reverse transcription to start and go?
@nl
P2860
P356
P1433
P1476
When is it time for reverse transcription to start and go?
@en
P2093
Jean-Luc Darlix
Laurent Houzet
P2860
P2888
P356
10.1186/1742-4690-6-24
P50
P577
2009-03-04T00:00:00Z
P5875
P6179
1001812522